The latest from Cogstate, leaders in optimizing the measurement of cognition

Big name boards are a boon for biotech

May 7, 2013

A number of small Australian biotechnology companies are beginning to turn a profit. Shares in Australian company Cogstate (ASX: CGS) have hovered under 40¢ for the past six months despite the company’s revenue rising 48 per cent to $12 million in 2012 and a net profit after tax of $2.5 million. It is conducting its first public trials […]

Education, health services appeal

May 1, 2013

AFR Small Caps writer, Jake Mitchell reported on the education and health testing services industry, featuring CogState’s computerised cognition test as one of the examples of the industry which caters to a large market opportunity in dementia and other psychological conditions. CogState’s deal with Merck Canada has also been referenced. Mitchell states, “CogState sells its […]

Take a gamble on market stocks

March 1, 2013

Herald Sun Criterion columnist, Tim Boreham reported on the Myer family’s 19.3 per cent investment in CogState and the use of Cognigram in Canada, which is the first test used outside of clinical trials for Alzheimers disease. Boreham states, “He (Brad O’ Connor) estimates the cognitive testing market globally is worth about $500m. Canada, in […]

Cognitive reasoning worth millions

March 1, 2013

Herald Sun’s In The Black columnist, John Beveridge reported on Cogstate’s tests and its applicability to a range of cognitive testing ranging from sports testing, cognitive training for athletes to improve performance as well as cognitive assessment for psychological conditions. Cogstate is rated as a speculative Buy. Beveridge states, “However, the really big opportunity for […]

Drive with Rafael Epstein

February 1, 2013

ABC Radio’s 3-6pm Drive program host, Rafael Epstein interviewed Brad O’Connor on Cogstate and its cognitive testing technology Download the full clip here. 

Nic Naitanui close to AFL return for West Coast

January 1, 2013

Braden Quartermaine of the Herald reported that key clearance winner Matt Priddis, who was concussed in the first quarter of last Sunday’s disastrous loss to Port Adelaide, must pass a Cogstate test before being cleared to play.  “He’s looking great, feeling good. He still has to fulfil some commitments in terms of the concussion stuff,” […]

Snapshot Stocks

January 1, 2013

Business analyst, Trevor Hoey reported on Cogstate in his Snapshot Stocks column regarding Cogstate’s upward share price momentum on the back of a $3.57 million grant awarded for their phase III clinical trial program and securing strong revenues of $8.5 million. Hoey states, “With an increasing focus on mental health both in Australia and overseas, […]

CogState publishes Alzheimers study

October 1, 2012

Finance News Network Joel Spreadborough reported that Cogstate researchers believe to have found a way to detect the early on-set of Alzheimer’s disease as well as the company’s earnings summary for the reporting period. Spreadborough states, “Cogstate posted a net profit of $2.5 million for the 2012 financial year.” Read the full article here. 

Snapshot Stocks

August 1, 2012

Respected analyst, Trevor Hoey reported on Cogstate as of one his featured stocks for the period. Cogstate was referenced for its partnership with Merck Canada and Axon Sports for marketing and distribution rights of the Cogstate test. Hoey states, “Increased focus on the early detection of neuro-degenerative diseases such as Alzheimer’s and schizophrenia should assist […]

1 6 7 8